Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD (PROSPECT)

Pfizer

Status: Terminated

Conditions: Sickle Cell Disease

Treatments: Drug: Oxbryta® (voxelotor) 500mg Tablets

Study type: Observational

Funder types: Industry

Identifiers

NCT04930445

C5341019 (Other Identifier)

GBT440-4R2

Details and patient eligibility

About

This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.

Full description

The study will be conducted at approximately 45 sites in the United States.

This registry is an observational study to evaluate the effects of Oxbryta in individuals with SCD. Any participant who is currently taking Oxbryta, or has been prescribed and will initiate treatment with Oxbryta, is eligible to participate. Eligible participants will receive treatment with Oxbryta as prescribed by their physician, as part of their usual care. Participants will be treated and evaluated per standard of care (SOC) and at the physician's discretion. This study will collect data that are recorded in the participants' medical records and other secondary data sources. Study data will be collected at regular intervals and entered in case report forms (CRFs) via an electronic data capture (EDC) system by the study staff. Participants will be considered to be on study for up to 5 years after their first dose of Oxbryta treatment, or until they withdraw their consent to participate, or are discontinued from the study. Treatment, including interruptions and restarting treatment, will continue at the discretion of the treating physician, and there are no pre-defined treatment requirements. Participants may receive any additional medications prescribed by their treating physician, or have any medical interventions that are deemed appropriate by the treating physician or study doctor. The participant or treating physician may discontinue Oxbryta at any time. Participants who discontinue treatment with Oxbryta earlier than 5 years will continue to be followed on study to collect clinical and quality of life (QoL) outcomes for up to 5 years after their first dose of Oxbryta treatment. Participant safety and tolerability will be assessed throughout the study data collection period by the study doctor and reported to the Sponsor.

Enrollment: 262 patients

Sex: All

Ages: 4+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who meet all the following criteria will be eligible for enrollment:

  1. Willing and able to provide written informed consent (aged ≥ 18 years), parental/ guardian consent and participant assent (aged ≥ 12 to <18 years) per local regulations, or pediatric participants (aged 4 to <12 years) with parental/guardian consent per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines
  2. Male or female participants with documented diagnosis of sickle cell disease (all genotypes)
  3. Undergoing treatment with Oxbryta according to the Oxbryta USPI

Exclusion criteria

• Participants meeting any of the following criteria will not be eligible for study enrollment:

  1. Current participation in an investigation clinical trial or expanded access program, in which the participant may be receiving voxelotor treatment.
  2. Medical, psychological, or behavioral condition that, in the opinion of the study doctor, would confound or interfere with evaluation of safety and/or effectiveness of the study drug, prevent compliance with the study protocol; preclude informed consent; or render the participant unable/unlikely to comply with the study procedures

Trial design

262 participants in 1 patient group

Oxbryta Product Registry

Treatment:

Drug: Oxbryta® (voxelotor) 500mg Tablets